

Please type a plus sign (+) inside the box → ☐

PTO/SB/21 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/018,963
International Filing Date	June 16, 2000
First Named Inventor	Wen Yang Wu
Group Art Unit	
Examiner Name	
Attorney Docket No.	150070.401USPC

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> Cited References (8) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
---	---	--

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Karl R. Hermanns	 <b>00500</b> PATENT TRADEMARK OFFICE
Signature		
Date	March 8, 2002	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Jennifer Hanan	
Signature		Date: 03/08/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wen Yang Wu et al.  
International Application No. : PCT/AU00/00680  
International Filing Date : June 16, 2000  
U.S. Application No. : 10/018,963  
For : ANTIVIRAL AGENTS  
Docket No. : 150070.401USPC  
Date : March 8, 2002

Commissioner for Patents  
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). These references were cited in the International Search Report for corresponding application PCT/AU00/00680.

References AK (EP 0290906), AM (JP 5-320117) and AN (JP 8-081314) on Form PTO-1449, are not written in English. Accordingly, a corresponding English language abstract is submitted with each foreign publication. Applicants respectfully submit that these English language abstracts provide an explanation to the references relevance.

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicant's duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Karl R. Hermanns  
Registration No. 33,507


jh:KRH

Enclosures:

Postcard  
Form PTO/SB/21  
Form PTO-1449  
Cited References (8)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

D:\NrPortbl\iManage\JENH\263762\_1.DOC



Sheet 1 of 1

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
150070.401USPCAPPLICATION NO.  
10/018,963

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Wen Yang Wu

INTERNATIONAL FILING DATE  
June 16, 2001

GROUP ART UNIT

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,472,416	09/18/84	Stetter et al.	424	269	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	EP 0290906	11/17/88	EP (+Abstract in English)		
	AL	WO 90/01874	03/08/90	WIPO		
	AM	JP 5-320117	12/03/93	JP (+Abstract in English)		
	AN	JP 8-81314	03/26/96	JP (+Abstract in English)		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	Sushil K. Starling, et al., "Anti-inflammatory & Anti-arrhythmic Activities of 1-(Alkanoylphenoxy/Thiophenoxy)-3-(N <sup>4</sup> -phenylpiperazinyl)propanes," <i>Indian Journal of Chemistry</i> 15B:715-719, August 1977.
	AP	Joseph T. Strupczewski et al., "3-[[Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D <sub>2</sub> /5-HT <sub>2</sub> Antagonists with Potential Atypical Antipsychotic Activity: Antipsychotic Profile of Iloperidone (HP 873) <sup>1</sup> ," <i>J. Med. Chem.</i> 38:1119-1131, 1995.
	AQ	Michael S. Malamas et al., "Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors of 5-Lipoxygenase," <i>J. Med. Chem.</i> 39:237-425, 1996.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).